The use of surrogate endpoints in trials including biliary tract cancers (BTC) is growing. While this may expedite drug approval and decrease costs, it may not always correlate with an overall surviva...

Many clinical questions, such as estimating survival differences between living donor (LDLT) and deceased donor liver transplantation (DDLT), are limited to observational studies and cannot be answere...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of liver disease and a looming public health threat [1]. Noninvasive biomarkers to predict future liver-related comp...